Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Real-world experience with CAR-T cell therapy in 9 AL amyloidosis pts (median 5 prior LOT; 7 triple-class refractory, 2 penta-drug, 7 had ASCT) shows 6 heme CR + 1 VGPR; MRD-negativity at 10⁻⁵ in 8 at median of 29 days.”
Title: AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy
Authors: Melinda SY Tan, Rahma Warsame, Ricardo D Parrondo, Eli Muchtar, Taxiarchis V. Kourelis, Francis K Buadi, Wilson I Gonsalves, Joselle Cook, Prashant Kapoor, Suzanne R Hayman, David Dingli, Moritz Binder, Nelson Leung, Vivek Roy, Taimur Sher, Erin Erin Wiedmeier-Nutor, Saurabh Chhabra, Rafael Fonseca, Nadine Abdallah, S. Vincent Rajkumar, Shaji K Kumar, Morie A Gertz, Yi Lin, Angela Dispenzieri
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
